HBM Healthcare Investments announces investment of USD 20 million in Viela Bio
Viela Bio, a privately held biotechnology company, today announced the successful completion of a USD 75 million private placement. HBM Healthcare Investments led the financing round and invested USD 20 million. Additional new investors include Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs, and Barer & Son Capital. Existing investors participating include Temasek Holdings. Since launch in February 2018, Viela raised more than USD 300 million.
The financing will support Viela in the anticipated regulatory filing and pre-commercial planning for its lead product candidate, inebilizumab, for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and allows to advance development of additional clinical candidates targeting autoimmune and inflammatory diseases.
Viela Bio, headquartered in Gaithersburg, Maryland, USA, is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. Visit www.vielabio.com for more information.
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at firstname.lastname@example.org